Mammalian cleavage factor 25 targets KLF14 to inhibit hepatic stellate cell activation and liver fibrosis
Cellular Signalling · 2023
DOI: 10.1016/j.cellsig.2023.110752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2023. Verfasst von Xiaoyan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China; The State Key Laboratory of Digestive Disease,…. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, PPAR gamma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
Liver fibrosis is primarily caused by the activation of hepatic stellate cells (HSCs), which results from chronic liver damage. Understanding the pathogenesis of HSC activation could identify new therapeutic targets to treat liver fibrosis. In this study, we examined the protective role of the mammalian cleavage factor I 25 kD subunit (CFIm25, NUDT21) in inhibiting hepatic stellate cell activation. CFIm25 expression was measured in liver cirrhosis patients and a CCl4-induced mouse model. Adeno-associated viruses and adenoviruses were used to alter hepatic CFIm25 expression in vivo and in vitro to investigate how CFIm25 functions in liver fibrosis. The underlying mechanisms were explored using RNA-seq and co-IP assays. Here, we found that CFIm25 expression was drastically decreased in activated murine HSCs and fibrotic liver tissues. CFIm25 overexpression downregulated the expression of genes involved in liver fibrosis, inhibiting the progression of HSC activation, migration and proliferation. These effects resulted from direct activation of the KLF14/PPARγ signaling axis. KLF14 inhibition abrogated the CFIm25 overexpression-mediated reduction in antifibrotic effects. These data reveal that hepatic CFIm25 regulates HSC activation through the KLF14/PPARγ pathway as liver fibrosis progresses. CFIm25 may be a novel therapeutic target for liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China; The State Key Laboratory of Digestive Disease, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China. Electronic address: fanxi0821@ncu.edu.cn.
Förderung
- Natural Science Foundation of Jiangxi Province
Zitieren
APA
Chen, X., Shi, W., Zhu, L., Zhou, X., & Wang, Y. (2023). Mammalian cleavage factor 25 targets KLF14 to inhibit hepatic stellate cell activation and liver fibrosis. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2023.110752
Vancouver
Chen X, Shi W, Zhu L, Zhou X, Wang Y. Mammalian cleavage factor 25 targets KLF14 to inhibit hepatic stellate cell activation and liver fibrosis. Cellular Signalling. 2023. doi:10.1016/j.cellsig.2023.110752
BibTeX
@article{Chen2023,
author = {Chen, Xiaoyan and Shi, Wenjie and Zhu, Liang and Zhou, Xiaojiang and Wang, Yunwu},
title = {Mammalian cleavage factor 25 targets KLF14 to inhibit hepatic stellate cell activation and liver fibrosis},
journal = {Cellular Signalling},
year = {2023},
doi = {10.1016/j.cellsig.2023.110752}
}
EUVIMED